SOURCE: Equity Markets Inc

September 26, 2011 09:00 ET

Global Situation & Resulting Influences - Research Report on SIGA Technologies, Inc. and ImmunoGen, Inc.

MACAU--(Marketwire - Sep 26, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting SIGA Technologies, Inc. (NASDAQ: SIGA) and ImmunoGen, Inc. (NASDAQ: IMGN). Full content and research is available at www.EquityMarketsInc.com/research.php?id=SIGA+IMGN.

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments," wary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

Equity Markets has reviewed SIGA Technologies, Inc. for its current position within the healthcare industry. SIGA Technologies, Inc. (SIGA), incorporated on December 28, 1995, is engaged in the research, development and commercialization of products for the prevention and treatment of serious infectious diseases, including products for use in defense against biological warfare agents, such as smallpox and Arenaviruses. The full research report on SIGA Technologies, Inc. (NASDAQ: SIGA) is available here: www.EquityMarketsInc.com/research.php?id=SIGA.

Equity Markets has reviewed ImmunoGen, Inc. for its development within the healthcare industry. ImmunoGen, Inc. (ImmunoGen) is focused on the development of antibody-based anticancer therapeutics. The full research report on ImmunoGen, Inc. (NASDAQ: IMGN) is available here: www.EquityMarketsInc.com/research.php?id=IMGN.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information